TITLE

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

AUTHOR(S)
Vos van Steenwijk, Peggy; Ramwadhdoebe, Tamara; Löwik, Margriet; Minne, Caroline; Berends-van der Meer, Dorien; Fathers, Lorraine; Valentijn, A.; Oostendorp, Jaap; Fleuren, Gert; Hellebrekers, Bart; Welters, Marij; Poelgeest, Mariette; Melief, Cornelis; Kenter, Gemma; Burg, Sjoerd
PUB. DATE
September 2012
SOURCE
Cancer Immunology, Immunotherapy;Sep2012, Vol. 61 Issue 9, p1485
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The aim of this study was to investigate the capacity of an HPV16 E6/E7 synthetic overlapping long-peptide vaccine to stimulate the HPV16-specific T-cell response, to enhance the infiltration of HPV16-specific type 1 T cells into the lesions of patients with HPV16+ high-grade cervical squamous intraepithelial lesion (HSIL) and HPV clearance. This was a placebo-controlled randomized phase II study in patients with HPV16-positive HSIL. HPV16-specific T-cell responses were determined pre- and post-vaccination by ELISPOT, proliferation assay and cytokine assays in PBMC and HSIL-infiltrating lymphocytes, and delayed-type hypersensitivity skin tests. Motivational problems of this patient group to postpone treatment of their premalignant lesions affected the inclusion rates and caused the study to stop prematurely. Of the accrued patients, 4 received a placebo and 5 received 1-2 vaccinations. Side effects mainly were flu-like symptoms and injection site reactions. A strong HPV-specific IFNγ-associated T-cell response was detected by ELISPOT in all vaccinated patients. The outcome of the skin tests correlated well with the ELISPOT analysis. The cytokine profile associated with HPV16-specific proliferation varied from robust type 1 to dominant type 2 responses. No conclusions could be drawn on vaccine-enhanced T-cell infiltration of the lesion, and there was no HPV clearance at the time of LEEP excision. Thus, vaccination of HSIL patients results in increased HPV16-specific T-cell immunity. Further development of this type of treatment relies on the ability to motivate patients and in the reduction in the side effects.
ACCESSION #
79340770

 

Related Articles

  • Perceived Stress is Associated with Impaired T-Cell Response to HPV16 in Women with Cervical Dysplasia. Fang, Carolyn Y.; Miller, Suzanne M.; Bovbjerg, Dana H.; Bergman, Cynthia; Edelson, Mitchell I.; Rosenblum, Norman G.; Bove, Betsy A.; Godwin, Andrew K.; Campbell, Donald E.; Douglas, Steven D. // Annals of Behavioral Medicine;2008, Vol. 35 Issue 1, p87 

    Infection with high-risk subtypes of human papillomavirus (HPV) is a central factor in the development of cervical neoplasia. Cell-mediated immunity against HPV16 plays an important role in the resolution of HPV infection and in controlling cervical disease progression. Research suggests that...

  • The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Vos van Steenwijk, Peggy; Poelgeest, Mariette; Ramwadhdoebe, Tamara; Löwik, Margriet; Berends-van der Meer, Dorien; Minne, Caroline; Loof, Nikki; Stynenbosch, Linda; Fathers, Lorraine; Valentijn, A.; Oostendorp, Jaap; Osse, Elisabeth; Fleuren, Gert; Nooij, Linda; Kagie, Marjolein; Hellebrekers, Bart; Melief, Cornelis; Welters, Marij; Burg, Sjoerd; Kenter, Gemma // Cancer Immunology, Immunotherapy;Feb2014, Vol. 63 Issue 2, p147 

    The capacity of a low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) to induce an HPV16-specific T-cell response as well as to establish long-term immunologic memory in patients with low-grade abnormalities of the cervix was determined in a placebo-controlled, double-blinded phase II...

  • Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Pollock, K G J; Kavanagh, K; Potts, A; Love, J; Cuschieri, K; Cubie, H; Robertson, C; Cruickshank, M; Palmer, T J; Nicoll, S; Donaghy, M // British Journal of Cancer;10/28/2014, Vol. 111 Issue 9, p1824 

    Background:In Scotland, a national HPV immunisation programme began in 2008 for 12- to 13-year olds, with a catch-up campaign from 2008 to 2011 for those under the age of 18. To monitor the impact of HPV immunisation on cervical disease at the population level, a programme of national...

  • p63 VALUE IN CERVICAL BIOPSY TISSUES. Plesa, Adriana; Bleotu, Coralia; Goia, Cristina Daniela; Botezatu, Anca; Popa, Elena; Nistor, Elena; Andrei, Florin; Anton, Gabriela // Central European Journal of Public Health;2008 Supplement, Vol. 16, pS62 

    Background: The relationship between HPV infections and disease of the human uterine cervix is well established, ranging from CIN (cervical intra-epithelial neoplasia) to SCC (squamous cell carcinoma). Several studies showed correlation between papillomavirus life cycle and differentiation...

  • Human Papilloma Virus Infection and Cervical Disease. Osborne, Newton G. // Journal of Gynecologic Surgery;Fall2002, Vol. 18 Issue 3, p117 

    Presents information on human papilloma virus (HPV) infection and cervical disease. Total number of HPV identified by scientists; Clinical manifestations; Recommendations of the U.S. Centers for Disease Control and Prevention for the prevention of the diseased; Information on the booklet...

  • Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Castañon, A; Tristram, A; Mesher, D; Powell, N; Beer, H; Ashman, S; Rieck, G; Fielder, H; Fiander, A; Sasieni, P // British Journal of Cancer;1/3/2012, Vol. 106 Issue 1, p45 

    Background:Cervical screening identifies many women with low-grade abnormalities. In vitro and in vivo studies have shown that diindolylmethane (DIM) could potentially halt (cervical) carcinogenesis. We report on a randomised controlled trial of the effect of DIM in women with low-grade cervical...

  • Predictive value of human papillomavirus type for histological diagnosis of women with cervical... Burger, M.P.M.; Hollema, H. // BMJ: British Medical Journal (International Edition);1/14/95, Vol. 310 Issue 6972, p94 

    Investigates whether analysis of human papillomavirus in cervical scrapes might help in the better selection of patients for loop electrosection at the first visit. Human papillomavirus types in relation to histological diagnoses in patients with two cervical smears showing mild or moderate...

  • Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. Reesink-Peters, N.; Helder, M.N.; Wisman, G.B.A.; Knol, A.J.; Koopmans, S.; Boezen, H.M.; Schuuring, E.; Hollema, H.; de Vries, E.G.E.; de Jong, S.; van der Zee, A.G.J. // Journal of Clinical Pathology;Jan2003, Vol. 56 Issue 1, p31 

    Examines whether the detection of either telomerase and its components or high risk human papillomavirus are of value in predicting the presence of cervical intraepithelial neoplasia grade II/III in women referred because of cervical cytology reports showing at most moderate dyskaryosis. Key...

  • COMMENTARY. Buntinx, Frank // Evidence Based Medicine;Nov2003, p187 

    The article presents the author's comments on a review made on a study concerning the accuracy of monolayer cytology (MLC) or human papillomavirus (HPV) testing more accurate than the conventional cervical smear (CCS) test for detecting cervical neoplasia.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics